RHINE
E871107
RHINE is a pivotal phase III clinical trial evaluating faricimab for the treatment of diabetic macular edema.
All labels observed (1)
| Label | Occurrences |
|---|---|
| RHINE canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T9807337 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: RHINE Context triple: [faricimab, clinicalTrial, RHINE]
-
A.
Rhine
The Rhine is one of Europe's most important rivers, historically serving as a vital trade route and cultural boundary from the Alps through Germany to the North Sea.
-
B.
Rhens
Rhens is a historic town on the Rhine River in western Germany, known for its medieval role as a meeting place of the prince-electors of the Holy Roman Empire.
-
C.
High Rhine
The High Rhine is a stretch of the Rhine River in Central Europe, flowing swiftly between Lake Constance and Basel and forming part of the border between Germany and Switzerland.
-
D.
Lower Rhine
The Lower Rhine is the downstream section of the Rhine River flowing from roughly Bonn through Germany and the Netherlands to the North Sea, known for its dense population, industry, and historical river landscapes.
-
E.
Old Rhine
The Old Rhine is a historic branch of the Rhine River in the western Netherlands that flows through cities such as Leiden before reaching the North Sea.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: RHINE Target entity description: RHINE is a pivotal phase III clinical trial evaluating faricimab for the treatment of diabetic macular edema.
-
A.
Rhine
The Rhine is one of Europe's most important rivers, historically serving as a vital trade route and cultural boundary from the Alps through Germany to the North Sea.
-
B.
Rhens
Rhens is a historic town on the Rhine River in western Germany, known for its medieval role as a meeting place of the prince-electors of the Holy Roman Empire.
-
C.
High Rhine
The High Rhine is a stretch of the Rhine River in Central Europe, flowing swiftly between Lake Constance and Basel and forming part of the border between Germany and Switzerland.
-
D.
Lower Rhine
The Lower Rhine is the downstream section of the Rhine River flowing from roughly Bonn through Germany and the Netherlands to the North Sea, known for its dense population, industry, and historical river landscapes.
-
E.
Old Rhine
The Old Rhine is a historic branch of the Rhine River in the western Netherlands that flows through cities such as Leiden before reaching the North Sea.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
clinical trial
ⓘ
phase III clinical trial ⓘ randomized controlled trial ⓘ |
| comparesWith | aflibercept ⓘ |
| developsDrugFor |
Genentech
ⓘ
Roche ⓘ |
| enrollsPatientsWith | center-involved diabetic macular edema ⓘ |
| evaluates | faricimab ⓘ |
| focusesOnOutcome |
maintenance of visual acuity gains
ⓘ
reduction of retinal edema ⓘ |
| hasAllocation | randomized ⓘ |
| hasConditionStudied | diabetic macular edema ⓘ |
| hasControlArm | aflibercept 2 mg every 8 weeks after loading ⓘ |
| hasExperimentalArm |
faricimab fixed dosing
ⓘ
faricimab personalized treatment interval ⓘ |
| hasGeographicScope | international ⓘ |
| hasIntervention | faricimab ⓘ |
| hasMasking | double-masked ⓘ |
| hasModality | biologic therapy ⓘ |
| hasOutcome |
demonstrated extended dosing intervals for faricimab in many patients
ⓘ
met primary endpoint of non-inferiority vs aflibercept in visual acuity gains ⓘ |
| hasPhase | phase III ⓘ |
| hasPrimaryEndpoint |
change in best-corrected visual acuity
ⓘ
non-inferiority to aflibercept in visual acuity gains ⓘ |
| hasRouteOfAdministration | intravitreal injection ⓘ |
| hasSecondaryEndpoint |
anatomical retinal outcomes
ⓘ
safety and tolerability ⓘ treatment durability ⓘ |
| hasStudyDesign |
active-controlled
ⓘ
double-masked ⓘ multicenter ⓘ randomized ⓘ |
| hasStudyType | interventional ⓘ |
| hasTherapeuticArea | ophthalmology ⓘ |
| investigatesIndication | diabetic macular edema ⓘ |
| isPartOfProgram | faricimab DME clinical development program ⓘ |
| isPivotalFor | regulatory approval of faricimab for diabetic macular edema ⓘ |
| relatedTrial | YOSEMITE ⓘ |
| sponsors |
Genentech
ⓘ
Roche ⓘ |
| studiesDrug | faricimab ⓘ |
| supportsIndication | faricimab for treatment of diabetic macular edema ⓘ |
| targetsPopulation | adults with diabetic macular edema ⓘ |
| therapeuticClassStudied | bispecific antibody targeting Ang-2 and VEGF-A ⓘ |
| trialPhase | phase III ⓘ |
| usesDosingRegimen |
fixed dosing arm
ⓘ
personalized treatment interval ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: RHINE Description of subject: RHINE is a pivotal phase III clinical trial evaluating faricimab for the treatment of diabetic macular edema.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.